|
1
|
Kedzia W, Sajdak S, Kedzia H and
Spaczyński M: Primary melanoma of the uterine cervix in a 19 year
old woman case report. Ginekol Pol. 68:386–389. 1997.PubMed/NCBI(In Polish).
|
|
2
|
Myriokefalitaki E, Babbel B, Smith M and
Ahmed AS: Primary malignant melanoma of uterine cervix FIGO IIa1: A
case report with 40 months ongoing survival and literature review.
Gynecol Oncol Case Rep. 5:52–54. 2013.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Pusceddu S, Bajetta E, Carcangiu ML,
Formisano B, Ducceschi M and Buzzoni R: A literature overview of
primary cervical malignant melanoma: An exceedingly rare cancer.
Crit Rev Oncol Hematol. 81:185–195. 2012.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Yuan G, Wu L, Li B and An J: Primary
malignant melanoma of the cervix: Report of 14 cases and review of
literature:. Oncotarget. 8:73162–73167. 2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Cantuaria G, Angioli R, Fernandez-Abril A
and Penalver M: Primary malignant melanoma of the uterine cervix:
Case report and review of the literature. Prim Care Update Ob Gyns.
5:159–160. 1998.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Kristiansen SB, Anderson R and Cohen DM:
Primary malignant melanoma of the cervix and review of the
literature Gynecol. Oncol. 47:398–403. 1992.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Noguchi T, Ota N, Mabuchi Y, Yagi S,
Minami S, Okuhira H, Yamamoto Y, Nakamura Y and Ino K: A case of
malignant melanoma of the uterine cervix with disseminated
metastases throughout the vaginal wall. Case Rep Obstet Gynecol.
2017(5656340)2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Jones HW III, Droegemueller W and Makowski
EL: Primary melanocarcinoma of the cervix. Am J Obstet Gynecol.
111:959–963. 1971.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Piura B: Management of primary melanoma of
the female urogenital tract. Lancet Oncol. 9:973–981.
2008.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Garbe C, Eigentler TK, Keilholz U,
Hauschild A and Kirkwood JM: Systematic review of medical treatment
for melanoma: Current status and future prospects. Oncologist.
16:5–24. 2011.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Bajetta E, Del Vecchio M, Nova P, Fusi A,
Daponte A, Sertoli MP, Queirolo P, Taveggia P, Bernengo MG, Legha
SS, et al: Multicenter phase III randomized trial of
polychemotherapy (CVD regimen) versus the same chemotherapy (CT)
plus subcutaneous interleukin-2 and interferon-alpha2b in
metastatic melanoma. Ann Oncol. 17:571–577. 2006.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Robert C, Karaszewska B, Schachter J,
Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R,
Grange F, Mortier L, et al: Improved overall survival in melanoma
with combined dabrafenib and trametinib. N Engl J Med. 372:30–39.
2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Kim MS, Choi CH, Kim TJ, Lee JW, Lee J,
Bae D and Kim BG: Primary malignant melanoma of the uterine cervix
treated with pembrolizumab after radical surgery: A case report and
literature review. Obstet Gynecol Sci. 61:524–528. 2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Indini A, Di Guardo L, Cimminiello C,
Lorusso D, Raspagliesi F and Del Vecchio M: Investigating the role
of immunotherapy in advanced/recurrent female genital tract
melanoma: A preliminary experience. J Gynecol Oncol.
30(e94)2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Anko M, Nakamura M, Kobayashi Y, Tsuji K,
Nakada S, Nakamura Y, Funakoshi T, Banno K and Aoki D: Primary
malignant melanoma of the uterine cervix or vagina was successfully
treated with nivolumab. J Obstet Gynaecol Res. 46:190–195.
2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
D'Angelo SP, Larkin J, Sosman JA, Lebbé C,
Brady B, Neyns B, Schmidt H, Hassel JC, Hodi FS, Lorigan P, et al:
Efficacy and safety of nivolumab alone or in combination with
Ipilimumab in patients with mucosal melanoma: A pooled analysis. J
Clin Oncol. 35:226–235. 2017.PubMed/NCBI View Article : Google Scholar
|
|
17
|
NCCN Clinical Practice Guidelines in
Oncology (NCCN Guidelines®) Cutaneous Melanoma Version
2.2019-March 12, 2019. https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf
in 2019.
|
|
18
|
Torres-Cabala CA, Wang WL, Trent J, Yang
D, Chen S, Galbincea J, Kim KB, Woodman S, Davies M, Plaza JA, et
al: Correlation between KIT expression and KIT mutation in
melanoma: A study of 173 cases with emphasis on the
acral-lentiginous/mucosal type. Mod Pathol. 22:1446–1456.
2009.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Hodi FS, Chapman PB, Sznol M, Lao CD,
Gonzalez R, Smylie M, Daniels GA, Thompson JA, Kudchadkar R,
Sharfman W, et al: Safety and efficacy of combination nivolumab
plus ipilimumab in patients with advanced melanoma: Results from a
North American expanded access program (CheckMate 218). Melanoma
Res. 31:67–75. 2021.PubMed/NCBI View Article : Google Scholar
|
